Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Peptide neuroprotection through specific interaction with brain tubulin.

Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I.

J Neurochem. 2006 Aug;98(3):973-84.

2.
3.

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

Gozes I, Divinski I.

J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41.

PMID:
15665412
4.

Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).

Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.

J Alzheimers Dis. 2014;40 Suppl 1:S23-36. doi: 10.3233/JAD-131664.

PMID:
24503616
5.

The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Oz S, Ivashko-Pachima Y, Gozes I.

PLoS One. 2012;7(12):e51458. doi: 10.1371/journal.pone.0051458. Epub 2012 Dec 14.

6.

A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication.

Divinski I, Mittelman L, Gozes I.

J Biol Chem. 2004 Jul 2;279(27):28531-8. Epub 2004 Apr 29.

7.

NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis.

Busciglio J, Pelsman A, Helguera P, Ashur-Fabian O, Pinhasov A, Brenneman DE, Gozes I.

Curr Pharm Des. 2007;13(11):1091-8.

PMID:
17430172
8.

Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL.

Holtser-Cochav M, Divinski I, Gozes I.

J Mol Neurosci. 2006;28(3):303-7.

PMID:
16691018
9.

Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

Shiryaev N, Pikman R, Giladi E, Gozes I.

Curr Pharm Des. 2011;17(25):2603-12. Review.

PMID:
21728979
10.

From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.

Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD.

J Mol Neurosci. 2003;20(3):315-22. Review.

PMID:
14501014
11.

NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).

Gozes I, Divinski I, Piltzer I.

BMC Neurosci. 2008 Dec 10;9 Suppl 3:S3. doi: 10.1186/1471-2202-9-S3-S3.

12.

Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking.

Thissen JA, Gross JM, Subramanian K, Meyer T, Casey PJ.

J Biol Chem. 1997 Nov 28;272(48):30362-70.

13.

The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy.

Zemlyak I, Manley N, Vulih-Shultzman I, Cutler AB, Graber K, Sapolsky RM, Gozes I.

J Neurochem. 2009 Dec;111(5):1252-63. doi: 10.1111/j.1471-4159.2009.06415.x. Epub 2009 Oct 3.

14.
16.

NAP mechanisms of neuroprotection.

Gozes I, Steingart RA, Spier AD.

J Mol Neurosci. 2004;24(1):67-72.

PMID:
15314252
17.

A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.

Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E.

J Pharmacol Exp Ther. 2001 Jan;296(1):57-63.

18.

NAP protects hippocampal neurons against multiple toxins.

Zemlyak I, Manley N, Sapolsky R, Gozes I.

Peptides. 2007 Oct;28(10):2004-8. Epub 2007 Aug 11.

PMID:
17869381
19.

Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation.

Shih AY, Erb H, Sun X, Toda S, Kalivas PW, Murphy TH.

J Neurosci. 2006 Oct 11;26(41):10514-23.

20.

Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate.

Gozes I, Spivak-Pohis I.

Curr Alzheimer Res. 2006 Jul;3(3):197-9. Review.

PMID:
16842095

Supplemental Content

Support Center